Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

Thursday, February 15, 2024 1 min read

Key Takeaway: Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

Full Press Release Details

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome.